MUC1 and interstitial lung disease: As early as 2000, Nakajima et al. evaluated serum KL-6 in SARD patients with and without ILD, demonstrating the potential of KL-6 as predictor of lung interstitial involvement and proposing it as a marker of disease activity [40].